Ombitasvir; Paritaprevir; Ritonavir Patent Expiration

1. Technivie patent expiration

TECHNIVIE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8642538 ABBVIE Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(5 years from now)

US8420596 ABBVIE Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(6 years from now)

US8691938 ABBVIE Anti-viral compounds
Apr, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6703403 ABBVIE Method for improving pharmacokinetics
Jun, 2016

(8 years ago)

US6037157 ABBVIE Method for improving pharmacokinetics
Jun, 2016

(8 years ago)

US6037157

(Pediatric)

ABBVIE Method for improving pharmacokinetics
Dec, 2016

(7 years ago)

US6703403

(Pediatric)

ABBVIE Method for improving pharmacokinetics
Dec, 2016

(7 years ago)

US7148359 ABBVIE Polymorph of a pharmaceutical
Jul, 2019

(4 years ago)

US7148359

(Pediatric)

ABBVIE Polymorph of a pharmaceutical
Jan, 2020

(4 years ago)

US7364752 ABBVIE Solid dispersion pharamaceutical formulations
Nov, 2020

(3 years ago)

US7364752

(Pediatric)

ABBVIE Solid dispersion pharamaceutical formulations
May, 2021

(3 years ago)

US8268349 ABBVIE Solid pharmaceutical dosage form
Aug, 2024

(a month from now)

US8399015 ABBVIE Solid pharmaceutical dosage form
Aug, 2024

(a month from now)

US8268349

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Feb, 2025

(7 months from now)

US8399015

(Pediatric)

ABBVIE Solid pharmaceutical dosage form
Feb, 2025

(7 months from now)

US9006387 ABBVIE Anti-viral compounds
Jun, 2030

(5 years from now)

US9044480 ABBVIE Compositions and methods for treating HCV
Apr, 2031

(6 years from now)

US8686026 ABBVIE Solid compositions
Jun, 2031

(6 years from now)

US8420596

(Pediatric)

ABBVIE Macrocyclic hepatitis C serine protease inhibitors
Oct, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 24, 2018
New Indication(I-743) Jul 24, 2018
New Chemical Entity Exclusivity(NCE) Dec 19, 2019

NCE-1 date: 19 December, 2018

Market Authorisation Date: 24 July, 2015

Treatment: Use of ritonavir as a potent cyp3a inhibitor to increase plasma drug concentration of paritaprevir and overall drug exposure for treatment of hcv infection; Treatment of hcv infection using ombitasvir...

Dosage: TABLET

More Information on Dosage

TECHNIVIE family patents

Family Patents